However, the human CRC cells tested in this paper expressed no or low levels of PDGFRβ (Tao et al., 2017), suggesting that the extensive enhancement in the in vitro binding of TRAIL to these CRC cells (Figure 2(D)) was not predominantly attributed to RGR-mediated PDGFRβ binding. The gene discussed is TNFSF10; the disease is colorectal carcinoma.